Contact Us
Contact Us
Blog Posts

Introducing Ben Kotopka, Director of Data Science

In today’s blog, we are pleased to introduce Ben Kotopka, Director of Data Science at Antheia. Ben’s work enables teams across the business to track and make sense of more than a decade of R&D data. We sat down with Ben to learn more about his background and what inspires him about working at Antheia:

Tell us about your background and career journey to Antheia.

I’ve been interested in genetic engineering since reading Jurassic Park as a child. This ultimately sparked my interest in metabolic engineering in high school and then led to studying molecular biology in undergrad at Princeton, followed by a PhD in bioengineering at Stanford.

During graduate school, I worked in our CEO and co-founder Dr. Christina Smolke’s lab. I wasn’t directly involved with the scientific work that led to Antheia’s founding, but I was an observer to the earlier parts of the story, and that drove me to rejoin the team later in my career so I could be part of the next chapter. I’m originally from eastern Nebraska and being from the Midwest, I’m very interested in new applications for the kind of agricultural work we do here.

After graduating, I collaborated with a fellow classmate on a brain MRI segmentation project that evolved into a startup called BrainKey. I was the co-founder and Chief Scientific Officer, which offered me a tremendous opportunity to see what it takes to build a startup – we were part of Y Combinator in 2019 and experienced the fundraising process firsthand. I learned that responsibility and flexibility are crucial. As a founder, there’s no room to say, “That’s not my job,” and I’ve kept that mindset throughout my journey.

When the pandemic hit, my career perspective shifted and I found myself wanting to get back into wet lab biology, which brought me to Antheia at first as a consultant and then with a full-time position as the head of data science in 2021.

Can you talk more about the field of data science and how you got into it?

Data science is still an emerging field. A lot of people in this line of work got started because they had a problem to solve that required them to pick up the skill set. We’re now seeing universities offer master’s degrees in data science, but your typical data scientist – myself included – likely does not have data science on the education section of their resume.

While at Stanford, I was working on ways to design artificial promoters, which are short DNA sequences that control the behavior of genes. The approach I took was measuring the activity of about a million randomly generated artificial promoters and then using that data to inform the design of new ones that would do what we wanted them to. This project was my entry point into the broader data science field.

In 2017, a friend of mine shared an article about recent progress using neural networks for images and I realized I could apply those techniques to the problem I was trying to solve at the time. I set up a basic experimental network, threw my data at it, and for the first time, I ended up with a system that seemed to understand what was going on in my artificial promoters.

What does your day-to-day work as Director of Data Science look like at Antheia?

Data science is like a pyramid. At the lowest levels, you have data integrity, ensuring we are not losing experimental information that we spend a lot of time and money collecting. In the middle, we should be able to easily access and visualize data, and then the top of the pyramid would be AI or an automated system pulling out insights from the data with less human intervention.

As the director of data science at Antheia, I’m responsible for all levels of that pyramid. On any given day, I could be writing code, coordinating a project, analyzing data, building a visualization, constructing a database, or sequencing the DNA of a strain. Since every aspect of our R&D team both generates and uses data, I work closely with biology, fermentation, bioanalytics, and downstream processing (DSP) to ensure that efficient systems are in place to best support our goals.

How important is data science throughout the R&D process?

Data science is critical. We’ve done tens of thousands of different experiments at the company over the years. Without putting some real thought and effort into a data strategy, those experiments would at best be logged in a stack of hundreds of excel spreadsheets with random names and storage methods, making it impossible to know what was done in 2018, for example, or how it informs what we’re doing today.

For the biology team, we need to keep track of what yeast strains they’ve built and how they’re related to each other genetically. They need to be able to see the difference between two strains, so I’ve created tools to help them do that more efficiently and effectively. The fermentation team runs 60 tanks a week, requiring many experimental and analysis steps, so software has had a big impact in more seamlessly orchestrating that work for fermentation and bioanalytics operators. It also allows them to effectively receive, store, and display the resulting data. The bioanalytics team takes hundreds of samples per week of our fermentation broth and analyzes the chemical composition. That data needs to be stored in an organized way so we can easily find it and leverage it in the future. The DSP team, which is responsible for refining the fermentation broth into a finished product, has the largest number of experiments and processes. DSP has to split and recombine samples in complex and varied ways as they test different refining strategies, and analyzing these results requires many different instruments. As a result, they need careful accounting of what’s been done over time.

At all levels, there are data science tools that are being used, developed, and maintained, and that’s where I come in. Without a data science team, you end up with a messy situation. Scaling a new technology and growing a business – especially in the sciences – is impossible without these systems in place.

What made you say yes to Antheia, first on a contractor basis and then eventually full-time? What inspires you about the work you’re doing?

I always wanted to work in metabolic engineering and when I learned about Christina’s lab at Stanford, I knew this was what I wanted to work on. As a reader and a lover of stories, it’s a privilege to feel that my work is part of a wonderful, potentially triumphant story. It’s a huge opportunity and personally, it’s something I have to see through.

I think a lot about self-reliance and sovereignty, especially how fragile the global supply chain has become. As a country, we could run into shortages of vital drugs if we don’t have the ability to produce them more efficiently here in the U.S. There’s a big opportunity for Antheia to help solve this if (or when) that ever becomes an issue. Moderna’s innovation and swift action during the COVID crisis is an excellent example of how advanced technologies like synthetic biology can – and should – be a part of our national strategy. You never wish for a crisis, but with climate change and geopolitics, more issues are arising that impact the availability of critical drugs through traditional routes. Knowing that Antheia is building the solution for these shortages is a big deal and I’m proud to be part of that.

How has your data science work impacted the path toward Antheia’s recent commercial milestones?

The team that figured out the strain and the process required to reach those milestones did so based on the results of thousands of experiments. Those results and the visualizations used to make decisions and the insights that drove progress were done with data science tools. While the team members are the main actors in the play, I’m the crew backstage making sure the stage lights are pointed in the right direction and the microphone is on – if I’m doing my job right, you won’t even know I’m there.

What are the hot topics and trends in data science and AI that you’re following?

One big area of progress is that the AI hype cycle is starting to calm down and we’re seeing a more balanced appraisal of the technology. We are beginning to view AI systems not as gods but as tools, which I think is a healthy shift. Currently, I’m interested in applications that help us handle unstructured data. Often, you have a “notes” field in experiment descriptions where scientists can add in context about their work. It’s an important feature that allows them to explain things in more detail, but that unstructured data is hard to analyze computationally years down the road. Generative AI might give us the ability to pull out valuable information from those notes at scale.

I’m also excited about the potential for AI in protein design, which is complementary to our work in pathway engineering. We’re trying to build a bridge from glucose to a target molecule, and AI seems like it’s becoming more tractable to design individual enzymes for that process, some of which may not even exist yet.

I don’t believe there’s a future where we give an entire data set to a machine and it replaces a team of scientists, but AI can complement the work we do. AI can’t match a human’s flexibility and ability to understand broad context, but we are seeing places where it can push us forward and I look forward to seeing how we can leverage it in our workflows.

What would you say makes Antheia a great place to work?

As a remote employee, there’s always been a great deal of trust. I’ve never felt micromanaged, and the leadership is confident and trusting, which inspires me to put my best foot forward. We have meetings where people engage with other departments with real interest, showing that everyone is not just focused on their piece of the puzzle, but on our overall mission. Maintaining the spirit of a small company with 50+ people speaks volumes about what’s been built at Antheia.

Follow Antheia on LinkedIn and Twitter/X.

Richard Sherwin

Head of Commercialization

Richard is an industry veteran with more than 30 years of experience in the KSM, API, and intermediate markets. He is responsible for leading the commercialization and revenue generation for Antheia’s robust pipeline of products. Richard brings an exceptional track record of leading international sales teams, driving revenue growth, building strategic partnerships, and delivering innovative products to market, including ANDA and NDA developments. Richard led commercial efforts at some of the leading global pharmaceutical companies and most recently, built his own consultancy business advising a range of clients, including $1B divisions of major multinationals.

Appropriate regulatory submissions will be prepared and submitted to support Antheia’s customers who need to reference and access necessary process-related information.

Yihui Zhu, PhD

Head of Fermentation

Yihui leads the fermentation team at Antheia. With over 25 years of hands-on experience in the field, he brings in-depth knowledge and expertise in microbial metabolism and fermentation process development. He is also skilled in developing comprehensive fermentation data collection, analysis, and visualization systems. Prior to joining Antheia, he served as a fermentation lead at Intrexon and Codexis where he successfully built fermentation labs and teams and led multiple biofuel and biochemical projects to reach stretch milestones and tech transfer. Yihui is passionate about the potential of fermentation and is dedicated to advancing the field through innovative research and development.

Yen-Hsiang Wang, PhD

Head of Strategy, Partnerships, and Finance

Yen-Hsiang leads strategy, partnerships and finance at Antheia. He completed his M.S. and Ph.D. in Bioengineering at Stanford, with extensive research experience in synthetic biology, metabolic engineering and computational modeling. Before joining Antheia, he worked at McKinsey and Tencent with a strong focus in corporate strategy and big data/advanced analytics. At Tencent, he served as Director of Strategy and Business Development for the AI Lab, leading corporate initiatives in healthcare AI/ML applications and commercialization. He also served in AI4H (Artificial Intelligence for Health), a collaboration between WHO and ITU, to establish global standards for AI in healthcare.

Audrey Wang

Head of Financial Planning and Analysis

Audrey leads financial planning and analysis at Antheia. With an MBA from Washington University in St. Louis, Audrey is passionate about leveraging financial analysis, digital technology, and data analytics to guide companies in making optimal investments and strategic business decisions. Audrey has a decade of experience in helping companies solve unique problems and creating long-term impact with unconventional approaches. Before joining Antheia, she was at Vir Biotechnology and Merck where she led various FP&A workstreams, including investment valuation, asset prioritization, and manufacturing sites operation finance support. Audrey completed CFA Level II and passed the U.S. CPA exam in 2011.

Antonij Tjahjadi, CPA

Head of Accounting

Antonij Tjahjadi leads accounting at Antheia and holds active CPA license. He joined Antheia with more than 20 years of experience in corporate accounting, bringing deep expertise in ramping up accounting operations for start-up companies, SEC reporting/technical accounting, and SOX implementation efforts. Before joining Antheia, he held various leading roles in both public and private company settings, including directing accounting functions at Ambys Medicines, where he successfully implemented Netsuite with Point Purchasing integration and set up various accounting policies and processes, and played a key role in the initial public offering of Nutanix, Inc.

Ken Takeoka

Head of Biology

Ken leads the Biology team at Antheia, which incorporates both strain and protein engineering functions. He has more than 16 years of experience in the synthetic biology field, working with leading companies, including Amyris and Novartis. One of his passions is molecular biology tool development and he previously worked to build the foundation for the automated strain engineering pipeline at Amyris. At Novartis, he modernized the molecular biology techniques and established a platform to model mechanisms of antibiotic resistance in a range of organisms.

Suzanne Sato

Head of Downstream Processing

Suzy leads downstream chemistry processes at Antheia. She has 19 years of experience in process development, including route development through synthetic chemistry and scale-up of small molecule APIs for GPCR targets under cGMP for Phase I-III trials. Before joining Antheia, Suzy led a full DSP team at Amyris where she successfully pivoted developments from biofuels hydrocarbon products to pharmaceutical intermediate, flavor, fragrance and nutraceutical products. She led a team that scaled 11 products and took five products to commercial manufacturing.

Farrah Pulce, PMP

Head of Project Management

Farrah leads program and project management at Antheia. She has over 20 years of experience leading program and project management, operations, and engineering for companies across the CPG, aerospace, and automotive industries. Prior to joining Antheia, Farrah implemented and led the sustaining program management team at Impossible Foods. She also led product operations, project management, and cost optimization at Blue Bottle Coffee and Tyson Foods to develop and commercialize new products. As a certified project management professional (PMP), Farrah has a proven record of successful project delivery, improving project management practices, and building collaborative teams.

Jordyn Lee

Head of Communications

Jordyn leads communications and external affairs at Antheia. She brings a decade of multidisciplinary communications experience in helping companies make complex science and technology accessible to broad audiences, all while maintaining technical accuracy and integrity. She has a passion for visionary storytelling and translating impact across the entire communications ecosystem – her work has spanned from public relations to corporate communications to marketing. Jordyn has served as an advisor to a number of different life sciences companies and most recently led corporate communications at Amyris.

Ben Kotopka, PhD

Head of Data Science

As Head of Data Science at Antheia, Ben manages in-house software development and external partnerships for storing and interpreting research data, executing bioinformatics analyses, and streamlining business processes. Prior to Antheia, Ben worked as an academic researcher at the intersection of machine learning, bioinformatics, and synthetic biology. Following this, as an entrepreneur and consultant, he developed and deployed data science solutions for biotechnology applications ranging from metabolomics-driven compound discovery to MRI segmentation.

Guerin Kob

Head of Supply Chain

Guerin is responsible for leading the design, development, management and improvement of Antheia’s end-to-end global supply chain. He has over 15 years of experience leading high-performing supply chain and procurement teams at leading biotechnology and specialty chemical companies, with extensive experience in process development and end-to-end supply chain optimization. Prior to joining Antheia, Guerin served as Senior Director of Global Supply Chain for Sumitomo Chemical’s biotechnology division with Valent Biosciences, where he led the end-to end supply chain including procurement, logistics and distribution, integrated business planning, materials management, customer service, and supply planning functions globally.

Pavel Aronov, PhD

Head of Bioanalytics

Pavel leads the Bioanalytics team at Antheia. He has 20 years of experience in analytical and clinical chemistry, mass spectrometry, chromatography, and metabolomics. Pavel built and led the original Chemistry and Analytics team at Impossible Foods enabling strain development, fermentation, DSP, regulatory, QC, and scale-up of leghemoglobin biomanufacturing. During his academic career at UC Davis and Stanford University Pavel developed a vitamin D assay used by all major clinical diagnostics laboratories and pioneered metabolomics studies to investigate kidney disease and microbiome.

Jesse Ahrendt

Head of Quality Assurance and Regulatory Affairs

Jesse has more than 25 years of experience in regulatory affairs, quality systems, manufacturing quality, and regulated industries, ranging from early- to late-stage pharmaceuticals, biomanufacturing, consumer care, and medical devices. He has supported global product launches and the underlying quality supply chain components in industries that require strict adherence to internationally accepted quality standards. Before Antheia, he led quality efforts at Zymergen and Sandoz, and supported many global pharmaceutical companies during his time in Biotech Consulting at NSF International, all to bring quality to the forefront in manufacturing, standardize global processes, and support customer regulatory requirements.

Heidi Pucel

Chief People Officer

Heidi is a results-driven human resources executive and HR business partner who leverages decades of experience in empowering, motivating, and inspiring to drive transformation within high-performing and rapidly-growing workforces. A certified executive coach and passionate advocate for people-oriented solutions, Pucel serves as a partner to executive teams to design programs that support employee development, engagement, and recruitment and retention. Pucel most recently served as Chief People Officer for Countsy, where she worked as an interim HR executive for clients in the biotechnology and software industries, such as Ceribell and Tune Therapeutics.

Zack McGahey

Chief Operating Officer

Zack is a leading executive in operations management, specializing in bioprocess engineering and manufacturing management. He has over 20 years of experience leading manufacturing functions for companies across the pharmaceutical, synthetic biology, diagnostics, and automotive industries. Before joining Antheia, Zack was VP of manufacturing and capex project management at Zymergen. He also gained experience managing commercial scale facilities operations for Tesla, where he was responsible for managing 10 million square feet of factory, lab and warehouse space during the Model 3 ramp.

Kristy Hawkins, PhD

Co-Founder & CSO

Kristy has over 20 years of experience in the field of synthetic biology, focusing on yeast metabolic engineering for the production of small molecules. She did the founding work on the benzylisoquinoline alkaloid pathway during her graduate studies and gained valuable industry experience at Amyris and Lygos. Kristy is an expert in tool development, high-throughput screening, and host strain and heterologous pathway engineering.

Christina Smolke, PhD

Co-Founder & CEO

Christina is a pioneer in synthetic biology and metabolic engineering, where she has over 20 years of experience. As Professor of Bioengineering and Chemical Engineering at Stanford University, her laboratory led the breakthrough research to engineer baker’s yeast to produce some of the most complex and valuable medicines known. Under her leadership, Antheia’s synthetic biology platform enables new possibilities for drug discovery and efficient, sustainable, transparent, and on-demand drug manufacturing at scale. Her vision and accomplishments have garnered numerous awards, including the Chan-Zuckerberg Biohub Investigator, NIH Director’s Pioneer Award, Nature’s 10, Novozymes Award for Excellence in Biochemical Engineering, and TR35 Award.

Antheia Secures Second BioMaP-Consortium Project Valued at $12M

Appropriate regulatory submissions will be prepared and submitted to support Antheia’s customers who need to reference and access necessary process-related information.